Literature DB >> 29027480

A Learning Collaborative Approach to Improve Primary Care STI Screening.

M Diane McKee1,2, Elizabeth Alderman3, Deborah V York4, Arthur E Blank1, Rahil D Briggs1,2, Kelsey E S Hoidal5, Christopher Kus6, Claudia Lechuga1, Marie Mann7, Paul Meissner1,2, Nisha Patel1, Andrew D Racine1,2.   

Abstract

The Bronx Ongoing Pediatric Screening (BOPS) project sought to improve screening for sexual activity and sexually transmitted infections (gonorrhea and chlamydia [GCC] and HIV) in a primary care network, employing a modified learning collaborative, real-time clinical data feedback to practices, improvement coaching, and a pay-for-quality monetary incentive. Outcomes are compared for 11 BOPS-participating sites and 10 non-participating sites. The quarterly median rate for documenting sexual activity status increased from 55% to 88% (BOPS sites) and from 13% to 74% (non-BOPS sites). GCC screening of sexually active youth increased at BOPS and non-BOPS sites. Screening at non-health care maintenance visits improved more at BOPS than non-BOPS sites. Data from nonparticipating sites suggests that introduction of an adolescent EMR template or other factors improved screening rates regardless of BOPS participation; BOPS activities appear to promote additional improvement of screening during non-health maintenance visits.

Entities:  

Keywords:  adolescent; primary care; quality improvement; sexually transmitted infection

Mesh:

Year:  2017        PMID: 29027480     DOI: 10.1177/0009922817733702

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  1 in total

1.  Exemplary Practices in Cardiovascular Care: Results on Clinical Quality Measures from the EvidenceNOW Southwest Cooperative.

Authors:  Douglas H Fernald; Rebecca Mullen; Tristen Hall; Andrew Bienstock; Stephanie Kirchner; Kyle Knierim; Dionisia de la Cerda; Danelle Callan; Robert L Rhyne; L Miriam Dickinson; W Perry Dickinson
Journal:  J Gen Intern Med       Date:  2020-08-17       Impact factor: 5.128

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.